AJOONI

Ajooni Biotech Financial Results

₹3.09+0.32%
Market cap
₹53.22 crore
P/E
12.3
P/B
0.58
ROE
4.8%
Dividend yield
1.20%

For the year ended Mar 2021, Ajooni Biotech reported revenue of ₹51 crore and net profit of ₹0 crore, against ₹74 crore and ₹1 crore a year earlier.

Ajooni Biotech annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Ajooni Biotech annual profit and loss (₹ crore)
ItemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026FY Mar 2026
Revenue51747480115182182
Expenses49717278111176176
Operating profit2332466
Operating margin %3%4%4%3%3%3%3%
Other income0002222
Interest1101011
Depreciation1111122
Profit before tax1123466
Tax %26%28%29%28%22%25%25%
Net profit0112344
EPS (₹)0.000.110.110.220.200.250.25
Dividend payout %———————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Ajooni Biotech financial results — frequently asked questions

What is Ajooni Biotech's annual revenue and net profit?

For the financial year ended Mar 2021, Ajooni Biotech's revenue was ₹51 crore and net profit ₹0 crore; net profit fell 100.00% from ₹1 crore in Mar 2022.

How fast has Ajooni Biotech grown over three years?

From Mar 2024 to Mar 2021, Ajooni Biotech's revenue grew at a compound annual rate of -13.9%. Past growth does not indicate future results.

What is the EPS of Ajooni Biotech?

Annual EPS for Mar 2021 was ₹0.00.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Ajooni Biotech With ATS

Track AJOONI live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.